PAVmed

PAVmed invites inquiries, feedback, and collaboration opportunities through a form for connecting with its team.

PAVmed is a commercial-stage, diversified medical technology company.

PAVmed, Inc. says its privacy policy explains information collected when visitors use pavmed.com, how it is used and disclosed, and options to review and correct it.

Medicare now covers Lucid Diagnostics’ EsoGuard esophageal DNA test, reimbursing $1,938 per test. The company secured $15 million in a private placement. Lucid Diagnostics develops molecular diagnostics for gastrointestinal diseases.

Oct 2026CLP MagazineNews article

Lucid Diagnostics starts processing Medicare reimbursements for its **EsoGuard** test under the Clinical Laboratory Fee Schedule. The company also secures **$15 million in financing** to support expansion and operational growth.

Oct 2026MorningstarNews article

Lucid Diagnostics expands reimbursement pathways for its **EsoGuard** and **EsoCheck** esophageal cancer screening tests. The company secures multiple payment, billing, and coding updates to improve accessibility for providers and patients. These tests detect precancerous conditions, enabling early intervention in high-risk individuals.

Sep 2026PR NewswireNews article

PAVmed Inc. releases its second-quarter 2026 financial results, detailing performance as a commercial-stage medical technology company. The company operates across diversified medical technology segments, though specific revenue or product details are not disclosed in the update. PAVmed highlights ongoing business activities while providing a snapshot of its financial standing for investors.

Aug 2026PR NewswireNews article